ALGS FY 2019 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$2M

Operating Income

-$54M

Net Income

-$52M

EPS (Diluted)

$-2.38

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$50M

Stock-Based Comp.

$752,000

Balance Sheet

Total Assets

$147M

Total Liabilities

$211M

Stockholders' Equity

-$65M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$2M	-$1M	-78.1%
Operating Income	-$54M	-$14M	-295.6%
Net Income	-$52M	-$14M	-275.1%